Sinotherapeutics Inc. (SHA:688247)
China · Delayed Price · Currency is CNY 8.95
-0.16 (-1.76%)
At close: May 21, 2026
Sinotherapeutics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 43.56 | 47.48 | 127.7 | 61.07 | 92.93 | 134.92 |
Depreciation & Amortization | 31.9 | 31.9 | 18.36 | 23.27 | 26.43 | 26.94 |
Other Amortization | 0.49 | 0.49 | 7.09 | 0.78 | 1.54 | 1.84 |
Loss (Gain) From Sale of Assets | - | - | - | -0.08 | -0.16 | 0.02 |
Asset Writedown & Restructuring Costs | 16.56 | 16.56 | -1.03 | 1.72 | -2.55 | 1.04 |
Loss (Gain) From Sale of Investments | -9.29 | -9.29 | -11 | -9.61 | -20.79 | -3.9 |
Stock-Based Compensation | - | - | - | - | - | 7.94 |
Provision & Write-off of Bad Debts | - | - | 3.93 | 0.81 | 1.43 | -0.29 |
Other Operating Activities | -16.76 | 4.73 | -2.06 | -1.22 | -5.31 | 4.25 |
Change in Accounts Receivable | 22.89 | 22.89 | -25.28 | -2.18 | -42.77 | -6.61 |
Change in Inventory | 14.43 | 14.43 | -16.46 | -56.47 | 13.83 | -0.05 |
Change in Accounts Payable | -17.75 | -17.75 | 17.53 | -4.11 | 12.6 | -52.23 |
Change in Other Net Operating Assets | -16.29 | -16.29 | 16.63 | -3.03 | -3.5 | 33.69 |
Operating Cash Flow | 69.92 | 95.33 | 130.23 | 12.96 | 73.18 | 145.77 |
Operating Cash Flow Growth | -58.15% | -26.80% | 905.01% | -82.29% | -49.80% | -30.60% |
Capital Expenditures | -31.34 | -41.56 | -94.93 | -38.96 | -176.34 | -16.01 |
Cash Acquisitions | - | - | - | - | -10.85 | - |
Investment in Securities | -20.22 | 148.9 | -399.89 | -84.41 | -20 | -52.6 |
Other Investing Activities | 9.83 | 9.64 | 10.98 | 15.79 | 6.88 | 4.38 |
Investing Cash Flow | -41.73 | 116.98 | -483.84 | -107.57 | -200.31 | -64.23 |
Long-Term Debt Repaid | - | - | -0.07 | -0.16 | -0.92 | -0.93 |
Net Debt Issued (Repaid) | - | - | -0.07 | -0.16 | -0.92 | -0.93 |
Issuance of Common Stock | - | - | - | - | 389.93 | - |
Repurchase of Common Stock | - | - | -36.15 | - | - | - |
Common Dividends Paid | -27.84 | -27.84 | -27.88 | -28.11 | - | - |
Other Financing Activities | -0.07 | -0.07 | - | - | -13.36 | - |
Financing Cash Flow | -27.91 | -27.91 | -64.09 | -28.27 | 375.65 | -0.93 |
Foreign Exchange Rate Adjustments | -5.36 | -3.29 | 1.71 | 1.52 | 2.97 | -2.9 |
Net Cash Flow | -5.08 | 181.1 | -416 | -121.36 | 251.5 | 77.71 |
Free Cash Flow | 38.58 | 53.77 | 35.3 | -26 | -103.15 | 129.77 |
Free Cash Flow Growth | -38.92% | 52.32% | - | - | - | -24.42% |
Free Cash Flow Margin | 8.93% | 12.04% | 6.90% | -8.67% | -41.67% | 41.13% |
Free Cash Flow Per Share | 0.09 | 0.13 | 0.08 | -0.06 | -0.24 | 0.32 |
Cash Income Tax Paid | 15.39 | 20.01 | 5.13 | 1.28 | 9.17 | 1.1 |
Levered Free Cash Flow | 93.59 | 63.41 | -22.06 | -42.85 | -150.44 | 30.86 |
Unlevered Free Cash Flow | 93.59 | 63.41 | -22.06 | -42.82 | -150.31 | 31.01 |
Change in Working Capital | 3.45 | 3.45 | -12.76 | -63.78 | -20.34 | -26.98 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.